Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction

Nature Medicine

Volumn 12, Issue 7, 2006, Pages 841-845

  Sauzeau, Vincent ^a,b   Sevilla, María A ^a,c   Rivas Elena, Juan V ^c   De Álava, Enrique ^a,b   Montero, María J ^a,c   López Novoa, José M ^c   Bustelo, Xosé R ^a,b  

^a CSIC   (Spain)

^b Salamanca Spain   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CAPTOPRIL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE; LOSARTAN; PROTEIN; RAC PROTEIN; RHO FACTOR; UNCLASSIFIED DRUG; VAV3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HOMEOSTASIS; HYPERTENSION; KIDNEY; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC NERVE CELL; SYMPATHETIC TONE; TACHYCARDIA;

ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENOTYPE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEMATOPOIESIS; HEMODYNAMIC PROCESSES; HOMEOSTASIS; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-VAV;

ANIMALIA;

EID: 33745929899     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1426     Document Type: Article

References (24)

1. Lifton, R.P., Gharavi, A.G. & Geller, D.S. Molecular mechanisms of human hypertension. Cell 104, 545-556 (2001).
2. Beevers, G., Lip, G.Y. & O'Brien, E. ABC of hypertension: the pathophysiology of hypertension. Br. Med. J. 322, 912-916 (2001).
3. Staessen, J.A., Wang, J., Bianchi, G. & Birkenhager, W.H. Essential hypertension. Lancet 361, 1629-1641 (2003).
4. Movilla, N. & Bustelo, X.R. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell. Biol. 19, 7870-7885 (1999).
5. Palatini, P. & Julius, S. Relevance of heart rate as a risk factor in hypertension. Curr. Hypertens. Rep. 1, 219-224 (1999).
6. Palatini, P. & Julius, S. The physiological determinants and risk correlations of elevated heart rate. Am. J. Hypertens. 12, 3S-8S (1999).
7. Bustelo, X.R. Regulatory and signaling properties of the Vav family. Mol. Cell. Biol. 20, 1461-1477 (2000).
8. Turner, M. & Billadeau, D.D. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat. Rev. Immunol. 2, 476-486 (2002).
9. Faccio, R. et al. Vav3 regulates osteoclast function and bone mass. Nat. Med. 11, 284-290 (2005).
10. Tybulewicz, V.L., Ardouin, L., Prisco, A. & Reynolds, L.F. Vav1: a key signal transducer downstream of the TCR. Immunol. Rev. 192, 42-52 (2003).
11. Fujikawa, K. et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J. Exp. Med. 198, 1595-1608 (2003).
12. Schmieder, R.E. & Messerli, F.H. Hypertension and the heart. J. Hum. Hypertens. 14, 597-604 (2000).
13. Intengan, H.D. & Schiffrin, E.L. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38, 581-587 (2001).
14. Takahashi, N. & Smithies, O. Gene targeting approaches to analyzing hypertension. J. Am. Soc. Nephrol. 10, 1598-1605 (1999).
15. Remuzzi, G., Perico, N. & Benigni, A. New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev. Drug Discov. 1, 986-1001 (2002).
16. DiBona, G.F. The sympathetic nervous system and hypertension: recent developments. Hypertension 43, 147-150 (2004).
17. Carrasco, G.A. & Van de Kar, L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463, 235-272 (2003).
18. Palatini, P. & Julius, S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin. Exp. Hypertens. 26, 637-644 (2004).
19. Palatini, P., Benetos, A. & Julius, S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 66, 133-144 (2006).
20. Turner, M. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7, 451-460 (1997).
21. Jerkic, M. et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 18, 609-611 (2004).
22. Flores, O. et al. Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp. Nephrol. 6, 39-49 (1998).
23. Chevillard, C., Brown, N.L., Mathieu, M.N., Laliberte, F. & Worcel, M. Differential effects of oral trandolapril and enalapril on rat tissue angiotensin-converting enzyme. Eur. J. Pharmacol. 147, 23-28 (1988).
24. Valdivielso, J.M. et al. Renal ischemia in the rat stimulates glomerular nitric oxide synthesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R771-R779 (2001).